Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The thread of life -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (1256)	1/29/2007 11:04:19 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 1336

Fierce 15 lists from past several years: fiercebiotech.com Fierce15 2003 Achillion Pharmaceuticals Aderis Pharmaceuticals Avalon Pharmaceuticals Elitra Pharmaceuticals Elixir Pharmaceuticals Eyetech Pharmaceuticals Fluidigm Gyros Immuno-Designed Molecules Memory Pharmaceuticals PatientKeeper Perlegen Sciences Raven Biotechnologies Spinal Concepts Theravance 2004 ARYx CombinatoRx Corus Pharma Cyberkinetics Deltanoid Diatos Eximias FivePrime Therapeutics Genomic Health Idenix Pharmaceuticals Kalypsys Kereos Micromet Synta Pharmaceuticals Therion Biologics 2005 Ambrx Arakis Ltd. BioVex Cellerant Therapeutics Ikaria Infinity Pharmaceuticals Molecular Insight Pharmaceuticals Neuro3d Rinat Neuroscience Somaxon Pharmaceuticals Speedel Tranzyme Pharma Verus Pharmaceuticals Wilex AG Xencor 2006 Affymax Ambit Biosciences ARCA Discovery Astex Therapeutics BioXell Bruin Pharmaceuticals Cerexa Domantis KAI Pharmaceuticals Microbia Neuromed Pharmaceuticals Optimer Pharmaceuticals PIramed Replidyne Trubion Pharmaceuticals

To: Mike McFarland who wrote (1256)	2/6/2007 12:27:23 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 1336

KineMed and Bayer Healthcare AG Enter Collaboration to Discover New Therapeutic Applications for Drug Candidates Feb 6 2007, 2:30 AM EST PRNEWSWIRE EMERYVILLE, Calif., Feb. 6 /PRNewswire/ -- KineMed, Inc., a pathway-based drug discovery and development company, and Bayer Healthcare AG announced today that they have signed an agreement to discover new therapeutic applications. Under the terms of the agreement, KineMed will identify new therapeutic utility by applying its proprietary translational medicine technologies (AquaTag(TM) and KineMarker(TM)). Once a disease target is established for a selected drug candidate, KineMed and Bayer Healthcare AG will jointly determine the best development and commercialization path. David Fineman, President and CEO of KineMed, commented, "The collaboration with Bayer Healthcare AG is an important opportunity for us to discover new indications for promising compounds and to work with Bayer Healthcare AG to pursue clinical development. This is in fact the third indications discovery deal we have announced in the past year, each of which gives us the option to move into more advanced product development." Mr. Fineman continued, "In addition to signing a partnership with Bayer Healthcare AG, we have over two dozen early-stage partnered collaborations that further validate our broad platform in translational medicine. In one program, we recently reported the advancement of the relationship to support clinical studies. Our goal over the next 12 months is to demonstrate further acceleration of these programs and to report dose-response and efficacy findings in Phase I, key evidence of our ability to de-risk clinical development."